Download Sample, Increasing Advances in Non-Invasive Methods Contributes to Market Growth
Increasing advances in non-invasive procedures and the rising prevalence of infectious diseases worldwide augmented the need for diagnostic tools for laboratory analysis. For instance, according to the Department of Biotechnology (DBT), infectious disease is the top ten cause of death in among the population, and is estimated by WHO report that around 704 million individuals are associated with different pathogens including 309 million children less than 5 years of age. Consequently, with rising awareness about early medical intervention and regular diagnostic testing limited access to traditional on-site blood sample collection laboratories, healthcare and research facilities and the absence of reliable transportation in remote areas led to advances in the healthcare field in adopting more remote healthcare options. Many market players are introducing novel and innovative methods in self-diagnostic testing tools and propelling the growth of the market.
For instance, in January 2024, ClinicSciences in collaboration with Trajan Scientific offered an expansion of the microsampling devices market of hempen and Mitra in France, Italy, Spain, and Portugal, enabling anyone to collect blood samples even at home by following instructions provided in sampling kit, making it ideal for blood sugar test and infectious diseases tests suited to both professional and layman. In addition, many self-diagnostic tools monitoring for infectious diseases such as non-variola orthopoxviral, monkeypox, and human papillomavirus are present in the market that allow minimal invasion methods and easy specimen collection features helping in decentralized clinical trials in remote areas also. For instance, in April 2024, Labcorp received FDA emergency use approval for the Mpox PCR Test Home Collection Kit for diagnosis of non-variola orthopoxviral infection and monkeypox virus in older patients. The diagnostic kit works on the principle of PCR technology present with a return laboratory package for disease analysis. Providing crucial diagnostic tools convenient testing options to patients and physicians and increasing the demand for specimen collection cards market.
In addition, the Abbott launched Cervi-Collect Specimen Collection Kit for HPV testing, using cervical canal samples containing a cervical brush and transport tube to stabilize DNA, allowing simplified sample collection using an automated sample preparation system helping to reduce manual steps and sampling errors, allowing less time consumption and minimum resource requirement to maintain the integrity of the sample. The increasing preference of specimen collection card testing is helping the market to grow.
For instance, in January 2024, ClinicSciences in collaboration with Trajan Scientific offered an expansion of the microsampling devices market of hempen and Mitra in France, Italy, Spain, and Portugal, enabling anyone to collect blood samples even at home by following instructions provided in sampling kit, making it ideal for blood sugar test and infectious diseases tests suited to both professional and layman. In addition, many self-diagnostic tools monitoring for infectious diseases such as non-variola orthopoxviral, monkeypox, and human papillomavirus are present in the market that allow minimal invasion methods and easy specimen collection features helping in decentralized clinical trials in remote areas also. For instance, in April 2024, Labcorp received FDA emergency use approval for the Mpox PCR Test Home Collection Kit for diagnosis of non-variola orthopoxviral infection and monkeypox virus in older patients. The diagnostic kit works on the principle of PCR technology present with a return laboratory package for disease analysis. Providing crucial diagnostic tools convenient testing options to patients and physicians and increasing the demand for specimen collection cards market.
In addition, the Abbott launched Cervi-Collect Specimen Collection Kit for HPV testing, using cervical canal samples containing a cervical brush and transport tube to stabilize DNA, allowing simplified sample collection using an automated sample preparation system helping to reduce manual steps and sampling errors, allowing less time consumption and minimum resource requirement to maintain the integrity of the sample. The increasing preference of specimen collection card testing is helping the market to grow.
Technological Advancement in Specimen Collection Fuels the Growth of Market
The rapidly changing technological landscape increasing the demands for safer and more efficient diagnostic procedures aimed at improving patient diagnostic outcomes to reduce invasive procedures of diseases such as idiopathic pulmonary fibrosis. According to the National Institute of Health (NIH), the prevalence of IPF in older individuals is approximately 85%, and per 10,000 individuals over 10.7% of cases in males and 7.4% of cases in females are registered. To reduce the number of invasive procedure cases many specimen collection card companies are stepping up to the plate by offering innovative and practical solutions to patients by using AI-powered tools and software. For instance, in January 2024, FDA approved Fibresolve an artificial intelligence diagnostic tool for early detection and intervention of high-risk patients by identifying patterns of idiopathic fibrosis and CT scan analysis. It is majorly used to provide timely and personalized treatment acting as an auxiliary tool for clinics by preventing the need of invasive and expensive testing.
Furthermore, AI technology is ascribed to the rise in awareness about early medical intervention of cognitive tests for dementia, Alzheimer and other impairment. According to WHO, more than 55 million people have dementia and around 60% are in low-income and high-income countries. Alzheimer's contributes around 60-70% of the cases, to reduce the cases of memory loss condition in the population many market players are innovative software that helps in early diagnosis. For instance, in January 2024, the FDA approved Brainsee an AI-powered software platform that uses scores from standard cognitive tests and MRI data that predict the probability of developing AD dementia in mild cognitively impaired individual within five years, enabling in appropriate treatments at an early stage of the disease process and expanding the opportunities for market players.
Furthermore, AI technology is ascribed to the rise in awareness about early medical intervention of cognitive tests for dementia, Alzheimer and other impairment. According to WHO, more than 55 million people have dementia and around 60% are in low-income and high-income countries. Alzheimer's contributes around 60-70% of the cases, to reduce the cases of memory loss condition in the population many market players are innovative software that helps in early diagnosis. For instance, in January 2024, the FDA approved Brainsee an AI-powered software platform that uses scores from standard cognitive tests and MRI data that predict the probability of developing AD dementia in mild cognitively impaired individual within five years, enabling in appropriate treatments at an early stage of the disease process and expanding the opportunities for market players.
Recent Trends in the Specimen Collection Cards Industry
- Increasing high demands for non-invasive procedures.
- Rising demand for the convenience of usage of diagnostic procedures.
- Increasing demand for sample stability at different temperatures.
- Growing demand for AI-powered tools and software.
Explore Our Breakthrough Market Segmentation and Personalize it to Meet Your Business Needs…!
Risk of Inaccurate Result and Sample Instability are Hindering the Growth of Market
The expected issues with maintaining sample integrity and storage are likely to hinder the specimen collection cards market, affecting the accuracy of testing results and requiring the maintenance of sample stability during diagnosis. Furthermore, this technology is susceptible to adverse effects from extreme conditions and environmental influences, such as temperature and humidity, which can lead to chemical reactions and result in altered outcomes. In addition, these tests are time-consuming and the limited availability of collection devices and testing facilities as well as the high risk of contamination from various sources, such as chemicals, bacteria, and environmental factors, can lead to inaccurate positive or negative tests results and improper disposable of samples can cause health issues to the public, thereby limiting the market growth.
Increasing Point of Care and Telemedicine Implementation Drives the Market Growth
The market is expanding because of the growing interest of the healthcare industry in telemedicine implementation and more convenient, safe, and accurate remote healthcare diagnostic tests for infants as well as old individuals. That can be used by anytime and anywhere helping in reducing material, shipping, and storage costs for sample collection. Specimen collection cards serve as indispensable means in infant screening providing a streamlined approach to collect blood samples quickly in order to initiate intervention.
Furthermore, the global focus on preventive healthcare measures for infants, such as required early screening for numerous rare disorders such as spinal muscular atrophy and severe combined immunodeficiency (SCID), acts as a keystone, helping the market's supremacy of specimen collection cards. According to NIH, SMA is a rare disease, and its prevalence is often cited as approximately 10 in 100,000 births, characterized by muscle weakness, affects shortened life expectancy. In addition, SCID is ian inherited primary autoimmune disorder, present by six months of age in infants leading to early death due to the absence of t and b cell function.
For instance, in November 2022, the FDA approved PerkinElmer’s EONIS SCID-SMA assay kit for diagnostic and detection of SMA and SCID in new-borns by using a single dried blood spot sample based on real real-time polymerase system using EONIS Analysis Software and EONIS DNA Extraction kit, contributing to increasing utilization of specimen collection cards in hospitals and clinics. In addition, in February 2023, Capitaner launched the Capitaner B50 self-sampling blood collection product, which collects five times more blood the conventional method. Providing non-invasive procedures and ease of use to implement more types of analysis and widespread adoption of specimen collection cards and contributing new opportunities for laboratories in low and middle-income countries.
QIAGEN, PerkinElmer AES, Eastern Business Forms, Inc, ARCHIMEDlife, Ahlstrom, GenTegra, FortiusBio, and CENTOGENE, are some of the prominent market players operating in the specimen collection cards market.
Furthermore, the global focus on preventive healthcare measures for infants, such as required early screening for numerous rare disorders such as spinal muscular atrophy and severe combined immunodeficiency (SCID), acts as a keystone, helping the market's supremacy of specimen collection cards. According to NIH, SMA is a rare disease, and its prevalence is often cited as approximately 10 in 100,000 births, characterized by muscle weakness, affects shortened life expectancy. In addition, SCID is ian inherited primary autoimmune disorder, present by six months of age in infants leading to early death due to the absence of t and b cell function.
For instance, in November 2022, the FDA approved PerkinElmer’s EONIS SCID-SMA assay kit for diagnostic and detection of SMA and SCID in new-borns by using a single dried blood spot sample based on real real-time polymerase system using EONIS Analysis Software and EONIS DNA Extraction kit, contributing to increasing utilization of specimen collection cards in hospitals and clinics. In addition, in February 2023, Capitaner launched the Capitaner B50 self-sampling blood collection product, which collects five times more blood the conventional method. Providing non-invasive procedures and ease of use to implement more types of analysis and widespread adoption of specimen collection cards and contributing new opportunities for laboratories in low and middle-income countries.
QIAGEN, PerkinElmer AES, Eastern Business Forms, Inc, ARCHIMEDlife, Ahlstrom, GenTegra, FortiusBio, and CENTOGENE, are some of the prominent market players operating in the specimen collection cards market.
Searching for a Country or Region Specific Report?
Unlock industry complexities with reports crafted for selected countries and regions at Reduced Cost
Increasing Infectious Disease Surveillance Demand and High Patient Footfall in North America Expands the Market
North America’s dominance in the specimen collection card market is attributed to its high patient footfall, varied testing requirements, and adherence to quality healthcare facilities. North America accounts for the maximum prevalence of infectious disease, every year around 23 million individuals seek clinical treatment, resulting in regular check-ups and early diagnosis awareness related to infectious disease. To get an early diagnosis of infections in the body, blood, urine, and other fluids are used mostly in spot-dried sample form that provides a swift and decentralized diagnostic process enabling seeking advice at an early point and upsurging the demand of diagnostic testing and disease surveillance consequential boosting the specimen collection market. In addition, increased centralized testing facilities, larger network integration between customers and market players and R&D activities among research institutes for the development of new specimen collection card technologies and AI-powered products will drive the North American market.
Europe can offer huge growth potential for the specimen collection card market with Finland leading the way. Wide applications in the preservation of DNA samples of plants, fungi, insects, and parasites at average thermal temperatures are driving the specimen collection card market. For instance, in April 2024, Ahlstrom launched Leafsaver, designed to transport DNA from plants, fungi, insects, and parasites without refrigerator preservation, allowing specimen preservation for over twenty years. Thus, reducing logistic cost and environmental impact enables significant advancement in plants and microbial preservation technology and allows scientists to examine the genetic makeup of various species-related diseases in humans, making research institutes key drivers of demand for specimen collection cards in the market.
The rapid prevalence of infectious diseases and regulatory healthcare rules is also boosting the demand in Europe. This is expected to create ideal conditions for market expansion. Furthermore, the specimen collection card market is expected to be the most profitable market in the Asia Pacific, owing to the increasing population and increasing purchasing power of customers enhances healthcare research, and developing economies such as China, India, and Indonesia are expected to drive the market demand.
Europe can offer huge growth potential for the specimen collection card market with Finland leading the way. Wide applications in the preservation of DNA samples of plants, fungi, insects, and parasites at average thermal temperatures are driving the specimen collection card market. For instance, in April 2024, Ahlstrom launched Leafsaver, designed to transport DNA from plants, fungi, insects, and parasites without refrigerator preservation, allowing specimen preservation for over twenty years. Thus, reducing logistic cost and environmental impact enables significant advancement in plants and microbial preservation technology and allows scientists to examine the genetic makeup of various species-related diseases in humans, making research institutes key drivers of demand for specimen collection cards in the market.
The rapid prevalence of infectious diseases and regulatory healthcare rules is also boosting the demand in Europe. This is expected to create ideal conditions for market expansion. Furthermore, the specimen collection card market is expected to be the most profitable market in the Asia Pacific, owing to the increasing population and increasing purchasing power of customers enhances healthcare research, and developing economies such as China, India, and Indonesia are expected to drive the market demand.
The report provides a detailed overview of the specimen collection cards market insights in regions including North America, Latin America, Europe, Asia-Pacific, Oceania, and the Middle East and Africa. The country-specific assessment for the specimen collection cards market has been offered for all regional market shares, along with forecasts, market scope estimates, price point assessment, and impact analysis of prominent countries and regions. Throughout this market research report, Y-o-Y growth and CAGR estimates are also incorporated for every country and region, to provide a detailed view of the specimen collection cards market. These Y-o-Y projections on regional and country-level markets brighten the political, economic, and business environment outlook, which are anticipated to have a substantial impact on the growth of the crop protection chemicals market. Some key countries and regions included in the specimen collection cards market report are as follows:
| North America | United States, Canada |
| Latin America | Brazil, Mexico, Argentina, Colombia, Chile, Rest of Latin America |
| Europe | Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Austria, Norway, Denmark, Finland, Ireland, Czech Republic, Rest of Europe |
| Asia Pacific | China, India, Japan, South Korea, Australia & New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific |
| Middle East and Africa | GCC Countries, South Africa, Egypt, Turkey, Morocco, Israel, Iran, Kenya, Nigeria, Rest of MEA |
Specimen Collection Cards Market Research Report Covers In-depth Analysis on:
- Specimen collection cards market detailed segments and segment-wise market breakdown
- Specimen collection cards market dynamics (Recent industry trends, drivers, restraints, growth potential, opportunities in Specimen Collection Cards industry)
- Current, historical, and forthcoming 10 years market valuation in terms of specimen collection cards market size (US$ Mn), volume (Units), share (%), Y-o-Y growth rate, CAGR (%) analysis
- Specimen collection cards market demand analysis
- Specimen collection cards market pricing analysis over the forecast period (by key segment and by region)
- Specimen collection cards market regional insights with a region-wise market breakdown
- Competitive analysis – key companies profiling including their market share, product offerings, and competitive strategies.
- Latest developments and innovations in the specimen collection cards market
- Regulatory landscape by key regions and key countries
- Supply chain and value chain analysis in the Specimen Collection Cards market
- Specimen Collection Cards market sales and distribution strategies
- A comprehensive overview of the parent market
- A detailed viewpoint on the Specimen Collection Cards market forecast by countries
- Mergers and acquisitions in the Specimen Collection Cards market
- Essential information to enhance market position
- Robust research methodology
- Frequently Asked Questions -
What factors are driving the growth of the specimen collection cards market?
Key growth drivers include advancements in medical diagnostics, rising demand for at-home testing kits, and increased focus on personalized healthcare and early disease detection.
What challenges do manufacturers face in the specimen collection cards market?
Manufacturers face challenges like stringent regulatory requirements, competition from alternative sampling technologies, and the need for high-quality, contamination-resistant materials.
What are the latest trends in the specimen collection cards market?
Trends include the development of eco-friendly cards, integration of smart tracking technologies, and growing demand for cards designed for specific diagnostic applications.
